arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Lyell Immunopharma, Inc.

LYEL

$14.66 ▲ +0.48 (+3.39%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Lyell Immunopharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $250.6M

Dividend Yield —

Revenue Growth -41.0% ↗

Op. Margin None

ROIC -85.7% ↘

FCF / Share $-8.82 ↗

Trailing P/E —

Price / Book 1.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$36.00K

↓ -41.0% —

Net Income Profit after all expenses

$-274.45M

↑ +20.0% —

FCF / Share Free cash flow per share

$-8.82

↑ +29.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	-41.0% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-612%)	-53.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-763%)	-99.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1348%)	695.1% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+8589%)	37.3% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+366%)	1080.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+13406%)	—	—
EPS Growth YoY (%)	38.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-41.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-25.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	59.8% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	88.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	34.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	20.0% Good ↑ Good Improving Year-over-year change in net income	-46.2% Weak ↓ Weak Declining Year-over-year change in net income	-28.1% Weak ↓ Weak Declining Year-over-year change in net income	26.8% Excellent ↑ Excellent Improving Year-over-year change in net income	-22.4% Weak Weak Year-over-year change in net income	-58.0% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	29.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	6.0% Fair ↓ Fair Declining Year-over-year change in free cash flow	15.5% Good Good Year-over-year change in free cash flow	44.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	-92.5% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-82.1% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-74.4% Weak Weak Compound annual revenue growth over 3 years	405.1% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-65.9% Weak Weak Compound annual revenue growth over 5 years	-37.8% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	-220.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1573%)	—	—	—	—
Profit Margin (%) (%)	—	—	—	-216.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1902%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	-228.9% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.55x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.47x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.71x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	1.04x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	-0.18x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-85.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-74.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-29.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-18.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	57.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	72.6% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-79.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-73.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-32.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-20.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-19.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-23.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-110.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-837%)	-89.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-697%)	-35.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-339%)	-22.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-247%)	-26.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-279%)	69.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+366%)	116.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+676%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-60.18M	$-105.60M	$-145.65M	$-123.55M	$-293.83M	$-140.41M	$-96.67M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.01	$6.85	$1.57	—	—	—
Basic EPS, GAAP (USD)	$-16.06	$-26.23	$-18.60	$-14.80	$-36.80	$-313.80	$-480.80	—
Free Cash Flow per Share (USD)	$-8.82	$-12.46	$-13.26	$-15.69	$-28.22	—	—	—
Book Value per Share (USD)	$11.68	$25.97	$51.58	$66.78	$76.61	$-375.76	—	—
Tangible Book Value per Share (USD)	$11.68	$25.97	$51.58	$66.78	$76.61	$-375.76	—	—
Basic Weighted Avg Shares (shares)	17.09M	13.07M	12.55M	12.35M	6.80M	663	271	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$211.53M	$325.81M	$520.17M	$614.27M	$579.55M	$568.26M	—	—
Total Equity (USD)	$248.20M	$382.82M	$654.95M	$833.25M	$929.79M	$-292.53M	$-111.11M	$850.00K

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$36.00K	$61.00K	$130.00K	$84.68M	$10.65M	$7.76M	$657.00K	—
Depreciation Expense (USD)	$11.54M	$19.63M	$20.25M	$18.02M	$13.62M	$4.29M	$1.26M	—
Net Income, GAAP (USD)	$-274.45M	$-342.99M	$-234.63M	$-183.12M	$-250.22M	$-204.47M	$-129.38M	—
Operating Cash Flow (USD)	$-150.02M	$-162.39M	$-163.69M	$-169.56M	$-126.25M	$-160.87M	$39.47M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters

Lyell Immunopharma, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare LYEL with peers